Cargando…
S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428250/ http://dx.doi.org/10.1097/01.HS9.0000967500.69905.66 |
| _version_ | 1785090422551347200 |
|---|---|
| author | Frustaci, Anna Maria Montillo, Marco Rossi, Davide Zinzani, Pier Luigi Motta, Marina Gaidano, Gianluca Quaresmini, Giulia Scarfò, Lydia Pietrasanta, Daniela Coscia, Marta Deodato, Marina Zamprogna, Giulia Cairoli, Roberto Stüssi, Georg Zucca, Emanuele Pileri, Stefano Zenz, Thorsten Tedeschi, Alessandra |
| author_facet | Frustaci, Anna Maria Montillo, Marco Rossi, Davide Zinzani, Pier Luigi Motta, Marina Gaidano, Gianluca Quaresmini, Giulia Scarfò, Lydia Pietrasanta, Daniela Coscia, Marta Deodato, Marina Zamprogna, Giulia Cairoli, Roberto Stüssi, Georg Zucca, Emanuele Pileri, Stefano Zenz, Thorsten Tedeschi, Alessandra |
| author_sort | Frustaci, Anna Maria |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428250 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104282502023-08-17 S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME Frustaci, Anna Maria Montillo, Marco Rossi, Davide Zinzani, Pier Luigi Motta, Marina Gaidano, Gianluca Quaresmini, Giulia Scarfò, Lydia Pietrasanta, Daniela Coscia, Marta Deodato, Marina Zamprogna, Giulia Cairoli, Roberto Stüssi, Georg Zucca, Emanuele Pileri, Stefano Zenz, Thorsten Tedeschi, Alessandra Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428250/ http://dx.doi.org/10.1097/01.HS9.0000967500.69905.66 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Frustaci, Anna Maria Montillo, Marco Rossi, Davide Zinzani, Pier Luigi Motta, Marina Gaidano, Gianluca Quaresmini, Giulia Scarfò, Lydia Pietrasanta, Daniela Coscia, Marta Deodato, Marina Zamprogna, Giulia Cairoli, Roberto Stüssi, Georg Zucca, Emanuele Pileri, Stefano Zenz, Thorsten Tedeschi, Alessandra S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME |
| title | S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME |
| title_full | S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME |
| title_fullStr | S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME |
| title_full_unstemmed | S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME |
| title_short | S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME |
| title_sort | s147: efficacy and safety results of molto, a multicenter, open label, phase ii clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in richter syndrome |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428250/ http://dx.doi.org/10.1097/01.HS9.0000967500.69905.66 |
| work_keys_str_mv | AT frustaciannamaria s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT montillomarco s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT rossidavide s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT zinzanipierluigi s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT mottamarina s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT gaidanogianluca s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT quaresminigiulia s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT scarfolydia s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT pietrasantadaniela s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT cosciamarta s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT deodatomarina s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT zamprognagiulia s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT cairoliroberto s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT stussigeorg s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT zuccaemanuele s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT pileristefano s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT zenzthorsten s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome AT tedeschialessandra s147efficacyandsafetyresultsofmoltoamulticenteropenlabelphaseiiclinicaltrialevaluatingvenetoclaxatezolizumabandobinutuzumabcombinationinrichtersyndrome |